Mattia A. Di Civita

Rome, 00161, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.

Journal: Cancer metastasis reviews

Published: April 02, 2026

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.

Journal: Targeted oncology

Published: March 30, 2026

Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).

Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).

Journal: Oncology and therapy

Published: January 26, 2026

Validation of a large language model as a decision tool for drug interaction in prostate cancer: A comparative study against UpToDate. Meet-URO 5/25 - GENIE study.

Validation of a large language model as a decision tool for drug interaction in prostate cancer: A comparative study against UpToDate. Meet-URO 5/25 - GENIE study.

Journal: Journal of geriatric oncology

Published: November 16, 2025

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Journal: Cancer immunology, immunotherapy : CII

Published: August 26, 2025

Exploring climate adaptation in European Merino sheep: a landscape genomics approach.

Exploring climate adaptation in European Merino sheep: a landscape genomics approach.

Journal: Animal : an international journal of animal bioscience

Published: June 06, 2025

First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials.

First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 13, 2025

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide.

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide.

Journal: Oncology reviews

Published: April 15, 2025

Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, an individual patients data metanalysis.

Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, an individual patients data metanalysis.

Journal: BMC cancer

Published: February 18, 2025

Real-Life Comparative Analysis of Robotic-Assisted Versus Laparoscopic Radical Prostatectomy in a Single Centre Experience.

Real-Life Comparative Analysis of Robotic-Assisted Versus Laparoscopic Radical Prostatectomy in a Single Centre Experience.

Journal: Cancers

Published: September 10, 2024

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Journal: Targeted oncology

Published: August 30, 2024

Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis.

Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: June 29, 2024

Showing 1-12 of 20

Last Updated: 09/26/2026